These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31380251)

  • 1. Preparation and Characterization of a Dry Powder Inhaler Composed of PLGA Large Porous Particles Encapsulating Gentamicin Sulfate.
    Shiehzadeh F; Tafaghodi M; Dehghani ML; Mashhoori F; Fazly Bazzaz BS; Imenshahidi M
    Adv Pharm Bull; 2019 Jun; 9(2):255-261. PubMed ID: 31380251
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of dry powder inhaler containing tadalafil-loaded PLGA nanoparticles.
    Varshosaz J; Taymouri S; Hamishehkar H; Vatankhah R; Yaghubi S
    Res Pharm Sci; 2017 Jun; 12(3):222-232. PubMed ID: 28626480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.
    Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI
    J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations.
    Devrim B; Bozkır A; Canefe K
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1376-86. PubMed ID: 21548727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery.
    Chvatal A; Ambrus R; Party P; Katona G; Jójárt-Laczkovich O; Szabó-Révész P; Fattal E; Tsapis N
    Int J Pharm; 2019 Mar; 559():68-75. PubMed ID: 30677482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and evaluation of inhaled Sildenafil-loaded PLGA microparticles for treatment of pulmonary arterial hypertension (PAH): A novel high drug loaded formulation and scalable process via hot melt extrusion technology (Part Ⅰ).
    Almutairi M; Hefnawy A; Almotairy A; Alobaida A; Alyahya M; Althobaiti A; Adel Ali Youssef A; Elkanayati RM; Ashour EA; Smyth HDC; Repka MA
    Int J Pharm; 2024 Apr; 655():124044. PubMed ID: 38527563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of highly porous large PLGA microparticles for pulmonary drug delivery.
    Yang Y; Bajaj N; Xu P; Ohn K; Tsifansky MD; Yeo Y
    Biomaterials; 2009 Apr; 30(10):1947-53. PubMed ID: 19135245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: In vitro and in vivo characterization.
    Ni R; Muenster U; Zhao J; Zhang L; Becker-Pelster EM; Rosenbruch M; Mao S
    J Control Release; 2017 Mar; 249():11-22. PubMed ID: 28109773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of Poly-Lactic-Co-Glycolic Acid Nanoparticles in a Dry Powder Formulation for Pulmonary Antigen Delivery.
    Scherließ R; Janke J
    Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, Statistical Optimization and
    Mehrabani Yeganeh E; Bagheri H; Mahjub R
    Iran J Pharm Res; 2020; 19(3):45-62. PubMed ID: 33680009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
    Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
    Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA Ethionamide Nanoparticles for Pulmonary Delivery: Development and in vivo evaluation of dry powder inhaler.
    Debnath SK; Saisivam S; Omri A
    J Pharm Biomed Anal; 2017 Oct; 145():854-859. PubMed ID: 28826144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.
    Chennakesavulu S; Mishra A; Sudheer A; Sowmya C; Suryaprakash Reddy C; Bhargav E
    Asian J Pharm Sci; 2018 Jan; 13(1):91-100. PubMed ID: 32104382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhalable oridonin-loaded poly(lactic-
    Zhu L; Li M; Liu X; Du L; Jin Y
    Acta Pharm Sin B; 2017 Jan; 7(1):80-90. PubMed ID: 28119812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.
    Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC
    AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties.
    Ambrus R; Benke E; Farkas Á; Balásházy I; Szabó-Révész P
    Eur J Pharm Sci; 2018 Oct; 123():20-27. PubMed ID: 30016647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-time and modular approach for quick detection and mechanism exploration of DPIs with different carrier particle sizes.
    Cui Y; Huang Y; Zhang X; Lu X; Xue J; Wang G; Hu P; Yue X; Zhao Z; Pan X; Wu C
    Acta Pharm Sin B; 2022 Jan; 12(1):437-450. PubMed ID: 35127397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation, optimization, and in vitro simulated inhalation delivery of carvedilol nanoparticles loaded on a coarse carrier intended for pulmonary administration.
    Abdelbary AA; Al-mahallawi AM; Abdelrahim ME; Ali AM
    Int J Nanomedicine; 2015; 10():6339-53. PubMed ID: 26491298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Targeting of Inhalable Moxifloxacin Microspheres for Effective Management of Tuberculosis.
    Vishwa B; Moin A; Gowda DV; Rizvi SMD; Hegazy WAH; Abu Lila AS; Khafagy ES; Allam AN
    Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33430162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.